VEGFA and non-small cell lung carcinoma: In patients with advanced non-small cell lung cancer aged ≥75 years, the high-serum VEGF group has been reported to have a lower ORR and DCR than those of the low-serum VEGF group, indicating that serum VEGF level is a predictive biomarker for the response to anti-PD-1 antibody treatment [17].